Immune Checkpoint Inhibition and the Prevalence of Autoimmune Disorders Among Patients With Lung and Renal Cancer
Open Access
- 1 January 2017
- journal article
- research article
- Published by SAGE Publications in Cancer Informatics
- Vol. 16
Abstract
Immune checkpoint inhibition reactivates the immune response against cancer cells in multiple tissue types and has been shown to induce durable responses. However, for patients with autoimmune disorders, their conditions can worsen with this reactivation. We sought to identify, among patients with lung and renal cancer, how many harbor a comorbid autoimmune condition and may be at risk of worsening their condition while on immune checkpoint inhibitors such as nivolumab and pembrolizumab. An administrative health care claims database, Truven MarketScan, was used to identify patients diagnosed with lung and renal cancer from 2010 to 2013. We assessed patients for diagnosis of autoimmune diseases 1 year prior to or after diagnosis of cancer using International Classification of Diseases, Ninth Revision codes for 41 autoimmune diseases. Baseline characteristics and other comorbid conditions were recorded. More than 25% of patients with both lung and renal cancer had a comorbid autoimmune condition between 2010 and 2013 and were more likely to be women, older, and have more baseline comorbidities. This population presents a dilemma to physicians when deciding to treat with immune checkpoint inhibitors and risk immune-related adverse events. Future evaluation of real-world use of immune checkpoint inhibitors in patients with cancer with autoimmune diseases will be needed.Keywords
This publication has 14 references indexed in Scilit:
- Prevalence of Autoimmune Disease Among Patients With Lung CancerJAMA Oncology, 2016
- Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancerBMJ Case Reports, 2016
- Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanomaJournal of Cutaneous Pathology, 2016
- Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy studyJournal for ImmunoTherapy of Cancer, 2016
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialThe Lancet Oncology, 2015
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010
- Administrative data based patient safety research: a critical reviewQuality and Safety in Health Care, 2003
- Comorbidity Measures for Use with Administrative DataMedical Care, 1998
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987